Bayer has entered a global exclusive license and collaboration with Kumquat Biosciences to develop and commercialize a KRAS G12D inhibitor, a mutation implicated in 25% of human cancers including pancreatic, colorectal, and non-small cell lung cancers. Kumquat will initiate Phase Ia trials following FDA clearance, with Bayer assuming development and commercialization thereafter. This agreement highlights Bayer’s commitment to expanding its precision oncology portfolio and tackling historically elusive targets.